Diabetes and obesity...Kakao Healthcare and Novo Nordisk Pharmaceuticals Sign a Business Agreement to Build a Digital Healthcare Ecosystem
Sep 03, 2025
|
At a business agreement ceremony held at Novo Nordisk headquarters in Songpa-gu, Seoul on the 2nd, attended by Hwang Hee, CEO of Kakao Healthcare, and Casper Rossille Poulsen, CEO of Novo Nordisk Pharmaceutical in Korea, the two companies decided to cooperate in creating a sustainable treatment environment that can produce better treatment results by improving the treatment journey for obese and diabetic patients using various digital technologies.
The two companies signed a business agreement in 2023 and are providing medication management solutions for diabetics by linking Kakao Healthcare's AI-based health care solution 'Pasta' with Novo Nordisk's smart cap 'Maliya' for insulin flex-touch pens.
This cooperation is significant in that it is an all-round cooperation that has expanded to the obesity area following diabetes. In response to the rapidly increasing demand for unmet medical care for obese and diabetic patients in Korea, it plans to provide patient-centered digital solutions.
In the obesity sector, ▲ patient-specific digital support programs ▲ work together to provide solutions for additional treatment effects and improved quality of life. In particular, Novo Nordisk Pharmaceutical will link the function of the patient support program 'Novo Fit Care' that is being provided to patients prescribed for their obesity treatment to the 'Pasta' app. Through this, we plan to help obese patients with long-term and comprehensive health care, including their weight. In the field of diabetes, digital solutions will be developed to improve disease awareness.
`Obesity and diabetes are chronic diseases that, if left unattended, cause serious comorbidities and cause enormous burdens on individuals and society,' said Casper Rosseu Poulsen, CEO of Novo Nordisk Pharmaceuticals in Korea."We expect that the collaboration between Novo Nordisk Pharmaceutical, which has been dedicated to diabetes and obesity for more than 100 years, and Kakao Healthcare, a leading digital healthcare company in Korea, will accelerate the integrated innovation of supporting obese and diabetic patients in Korea."," he said.
Hwang Hee, CEO of Kakao Healthcare, said "Kakao Healthcare has led positive changes in the patient's health journey based on various technologies such as AI and big data"We expect this experience and technology to play a major role in expanding patient-centered digital healthcare globally with Novo Nordisk Pharmaceuticals, a leading company in the treatment of obesity and diabetes."
This article was translated by Naver AI translator.
